One Comprehensive Universal Radiotherapy for Everyone (1-CURE) supports cross-disciplinary teams developing a single, low-cost radiotherapy treatment to eliminate local and metastatic tumors and prevent recurrence.
1-CURE is no longer accepting new submissions; ARPA-H is reviewing submitted proposals and will announce awards after negotiations are complete. The program’s FAQ page is also no longer available.
CRI Clinic and Laboratory Integration Program supports investigator teams translating cancer immunology discoveries into immune-based approaches to prevent initial cancer development and recurrence.
CRI Technology Impact Award supports technology developers and clinical cancer immunologists in creating unbuilt, untested technologies to overcome barriers and enable more effective cancer immunotherapies.
CRI Clinical Innovator supports academic researchers leading early-phase cancer immunotherapy trials to test novel treatments, study response mechanisms, and identify biomarkers to improve patient outcomes.
This grant funds research to develop and test precision drug-radiation combination therapies that exploit tumor-specific vulnerabilities, aiming to improve cancer treatment outcomes.
Catapult Award supports researchers conducting Phase 1 and Phase 2 pediatric cancer trials to move promising laboratory discoveries into patient care and develop better, less-toxic treatments for children.